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Abstract
Objective: To quantify the relative contribution of elevated 2-hr glucose, fasting glucose (FPG), and HbA1c to all-cause mortality.
Study Design and Setting: A joint analysis of two prospective studies with baseline glycemia measurements.
Results: The multivariate adjusted hazard ratios (HRs) corresponding to a one standard deviation increase in HbA1c were 1.14 (95%
CI 1.03–1.25), 1.08 (0.98–1.19) for FPG and 1.15 (1.05–1.27) for 2-hr glucose, respectively. Entering the 2-hr glucose to the model based
on the FPG and HbA1c significantly improved the prediction of mortality, whereas neither FPG, nor HbA1c added significant information once
2-hr glucose was in the models. In subjects with FPG 7.0 mmol/L and HbA1c 6.5%, the HR was 1.35 (1.03–1.78) in men with
2-hr glucose 7.8 mmol/L compared with men with 2-hr glucose 7.8 mmol/L.
Conclusion: Elevated 2-hr glucose was a predictor of mortality independent of the levels of fasting glucose and HbA1c.  2004
Elsevier Inc. All rights reserved.
Keywords: HbA1c; 2-Hour glucose; Fasting glucose; All-cause mortality* Corresponding author. Tel.: 358-9-191-27341; fax: 358-9-191-27313.




Recent studies have shown that 2-hr glucose is an inde-
pendent risk factor for all-cause and cardiovascular mortality
in subjects not previously diagnosed as diabetic and a better
predictor of mortality than fasting glucose (FPG) [1–7]. The
DECODE (Diabetes Epidemiology: Collaborative analysis
Of Diagnostic criteria in Europe) Study [1–3] revealed that
mortality increased with increasing 2-hr glucose concentra-
tion after a 75-g oral glucose load within any category of
fasting glucose, and that the largest absolute number of excess
deaths were attributed to impaired glucose tolerance. In con-
trast, such trend with increasing fasting glucose levels for
the 2-hr glucose categories was not found. Postprandial hy-
perglycemia, but not fasting hyperglycemia, was an indepen-
dent risk factor for myocardial infarction and total mortality
in the Diabetes Intervention Study [4]. Isolated postchallenge
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doi: 10.1016/j.jclinepi.2003.10.007he 2-hr glucose alone, has been found to double the mortal-
ty risk in middle-aged populations [5] and as well as in
lder women [6]. Postprandial plasma glucose level, but not
asting glucose level was independently associated with an
ncreased carotid intima-media thickness [7]. More recently,
he data analysis based on the five Finnish DECODE cohorts
howed that in subjects without a prior history of diabetes the
ssociation of 2-hr glucose with serious coronary heart dis-
ase (CHD) incidence (CHD death and nonfatal myocardial
nfarction) is graded and independent, and that 2-hr glucose is
uperior to fasting glucose in assessing the risk of future
HD events [8]. These studies, however, did not account
or HbA1c, which is an indicator for the average level of
lycemia over several months. The predictive value of
bA1c for mortality in the general population is less known.
n one prospective study [9], HbA1 but not 2-hr or fasting
lucose was related to cardiovascular mortality but not to
all-cause mortality in women only. In contrast, 2-hr glucose
was shown to be a better predictor for all-cause mortality
than FPG or HbA1c in the Hoorn study [10], as well as in the
ramingham Offspring study [11]. Also, Khaw et al. [12]
eported that HbA1c was continuously related to subsequent
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596 591mortality from all-cause, cardiovascular, and ischemic heart
disease across the whole population distribution of HbA1c,
with the lowest rates in people whose HbA1c concentration
was below 5%. However, data on FPG or 2-hr glucose was
not available in this latter study. In the present study, data
from two DECODE cohorts were analyzed to quantify simul-
taneously the relative contribution of fasting, 2-hr glucose,
and HbA1c to all-cause mortality in men.
2. Subjects and methods
2.1. Subjects and cohorts
Two population-based studies that have been included in
the DECODE study contributed their data to this joint analy-
sis. The Hoorn Study is a cohort study of glucose intolerance
in a Dutch population aged 49–77 years, which started in
1989 [10,13,14]. The Finnish cohort was first examined
in 1959 in connection with the Seven Countries Study [15–
17], and the glucose tolerance test was administrated to the
survivors of the cohort in 1989 when the population was
70–89 years old [18,19]. Subjects with insulin or oral hypo-
glycemic medication at baseline were classified as pre-
viously diagnosed diabetic and excluded from the current
data analysis. Men not previously diagnosed as diabetic and
having baseline glycemic measurements on HbA1c and on
plasma glucose at fasting and 2-hr after a 75-g oral glucose
tolerance test and having all other risk factors required
for the analysis were included in the data analysis. A total
of 1,097 men were from the Hoorn Study and 314 men from
the Finnish cohort. Vital status was collected for all subjects
from the population register of the city of Hoorn as of the
end of 1999 in the Hoorn cohort and from the National
Death Register as of the end of 1997 in the Finnish cohort.
The median follow-up was 8.8 years for the Hoorn cohort and
8.1 years for the Finnish cohort, and a total of 11,005 person-
years were accumulated.
The cohorts and the baseline measurements have been
described in detail previously [10,13–19]. Briefly, a fasting
blood sample was taken from all participants after overnight
fasting, and then, an oral 75-g glucose load was given.
Fasting and 2-hr postload plasma glucose concentrations
were determined with a glucose dehydrogenase method in
the both cohorts. HbA1c was determined by ion-exchange
high-performance liquid chromatography in both cohorts
at the time of the baseline surveys. Fasting insulin was
determined using a specific double-antibody radioimmuno
assay (Linco, St. Louis, MO) in the Hoorn Study and Phade-
seph Insulin RIA100 (Pharmacia Diagnostics AB, Uppsala,
Sweden) in the Finnish cohort. In both cohorts, cardiovascu-
lar risk factors, including total, high-density lipoprotein
(HDL), and low-density lipoprotein (LDL) cholesterol, tri-
glycerides, blood pressure, height, and weight were also
determined. Body mass index (BMI) was calculated by di-
viding the weight (kg) by height (m) squared. Smoking status



















































HbA1c concentration was classified into quintiles, and the
aseline risk factors were computed for the five categories of
bA1c (Tables 1 and 2). The linear trend between HbA1c
nd the continuous variables was tested using linear regres-
ion adjusted for age and for categoric variables using chi-
quare test. To ensure a more symmetric distribution, fasting
nsulin was natural logarithmically transformed, and the geo-
etric mean of fasting insulin was reported.
The hazard ratios for all-cause mortality were estimated
sing the Cox proportional hazard model for each cohort
eparately first, then for both cohorts combined. Adjust-
ent was made first for age and center, and then additional
djustment for body mass index, systolic blood pressure,
erum HDL-cholesterol, triglycerides, and smoking status.
DL-cholesterol and logarithmically transformed fasting in-
ulin was fitted in the initial multivariate model but were not
ncluded in the final model because they did not significantly
mprove the model. To make the hazard ratios comparable
etween HbA1c, FPG, and 2-hr glucose, the hazard ratio
or a one standard deviation increase, and for the upper 20%
nd middle 40% of the glycemic distributions compared
ith the lower 40% of the distributions were estimated. The
hree glycemic variables were estimated one by one in
hree separate models. Hazard ratios for combined categories
f glycemic variables were also estimated. The interaction
erms of center with glycemic variables and with all other
onfounding variables were modeled. The chi-square test
tatistic for measuring study-to-study variation in effect size
as performed using a fixed-effects approach according to
leiss [20]. The hypothesis of the test is that the two studies
re homogeneous with respect to their effect sizes.
A chi-squared log-likelihood ratio test was used to test
hether the predictive effect of HbA1c depended on 2-hr
r fasting glucose levels and vice versa, modeling with con-
inuous glycemic variables. SPSS for Windows 10.0 was
sed for statistic analysis.
. Results
There were 156 deaths and 1,954 person-years accumu-
ated in the Finnish cohort and 177 deaths and 9,051 person-
ears accumulated in the Hoorn cohort. The crude mortality
ate (79.8/1,000 person-years) was higher in the elderly Finn-
sh men than in the Dutch men (19.6/1,000 person-years),
s expected from age. Mortality increased with increasing
bA1c levels (see Tables 1 and 2). The cutoff values for
he quintiles of HbA1c were slightly higher in the elderly
innish men than in the Dutch men. Mean 2-hr glucose
oncentrations were much higher in the elderly Finnish men
han in the Dutch men in each HbA1c category, whereas
ean FPG concentrations did not differ much between the
wo studies. Mean age was higher with increasing HbA1c
evels in the Dutch men, but the increase was observed only
or the highest quintile of the HbA1c in the elderly Finnish
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596592Table 1
Baseline characteristics and mortality during the follow-up in subjects without a prior history of diabetes according to quintiles of HbA1c
in Dutch men in the Hoorn study
Quintiles of HbA1c distribution (%)
5.0 5.1–5.2 5.3–5.5 5.6–5.7 5.8 P-value
No. (%) 246 (22) 184 (17) 273 (25) 150 (14) 244 (22)
Age (years) 59 (0.5) 60 (0.5) 62 (0.4) 62 (0.6) 63 (0.5) .001
HbA1c (%) 4.7 (0.03) 5.2 (0.03) 5.4 (0.03) 5.6 (0.04) 6.2 (0.03)
Plasma glucose (mmol/L)
Fasting 5.4 (0.07) 5.5 (0.08) 5.6 (0.06) 5.6 (0.08) 6.3 (0.07) .001
2-h 5.4 (0.18) 5.4 (0.21) 5.5 (0.17) 5.9 (0.23) 7.3 (0.18) .001
Fasting insulin (µU/L)a 77.4 (1.03) 79.0 (1.03) 77.7 (1.03) 82.4 (1.04) 80.6 (1.03) .02
Body mass index (kg/m2) 25.8 (0.2) 26.0 (0.2) 26.2 (0.2) 26.4 (0.2) 26.4 (0.2) .001
Blood pressure (mmHg)
Systolic 136 (1.2) 135 (1.4) 134 (1.1) 137 (1.5) 135 (1.2) .64
Diastolic 84 (0.6) 84 (0.7) 83 (0.6) 83 (0.8) 83 (0.6) .78
Cholesterol (mmol/L) 6.2 (0.07) 6.3 (0.08) 6.4 (0.07) 6.6 (0.09) 6.7 (0.07) .001
HDL-cholesterol (mmol/L) 1.2 (0.02) 1.3 (0.02) 1.2 (0.02) 1.2 (0.03) 1.1 (0.02) .001
LDL-cholesterol (mmol/L) 4.3 (0.07) 4.3 (0.08) 4.5 (0.06) 4.7 (0.08) 4.7 (0.07) .05
Triglycerides (mmol/L) 1.5 (0.06) 1.5 (0.07) 1.5 (0.06) 1.7 (0.08) 2.1 (0.06) .001
Current smoking (%) 31.3 39.7 39.9 38.0 55.3 .001
Follow-up (years) 8.2 (0.12) 8.2 (0.14) 8.4 (0.11) 8.3 (0.15) 8.1 (0.12) .08
All-cause mortality, % (n) 9.3 (23) 12.5 (23) 13.9 (38) 20.7 (31) 25.4 (62) .001
Results are age-adjusted mean (standard error) except for noted.
a Geometric mean.with increasing HbA1c in both cohorts. The Pearson’s corre-
Table 2
Baseline characteristics and mortality during the follow-up in subjects without a prior history of diabetes according to quintiles of HbA1c in Finnish
men in the East and West Finland
Quintiles of HbA1c distribution (%)
5.0 5.1–5.3 5.4–5.5 5.6–6.1 6.2 P-value
No. (%) 68 (21) 68 (21) 47 (15) 71 (23) 60 (19)
Age (years) 76 (0.5) 76 (0.5) 76 (0.7) 76 (0.5) 77 (0.6) .52
HbA1c (%) 4.8 (0.03) 5.2 (0.03) 5.5 (0.04) 5.8 (0.03) 6.6 (0.03)
Plasma glucose (mmol/L)
Fasting 5.5 (0.09) 5.5 (0.09) 5.7 (0.11) 5.9 (0.09) 6.2 (0.10) .001
2-hour 7.2 (0.32) 6.8 (0.32) 7.8 (0.38) 7.5 (0.31) 9.0 (0.34) .001
Fasting insulin (µU/L)a 51.9 (1.10) 50.7 (1.10) 61.3 (1.12) 56.1 (1.09) 71.7 (1.10) .003
Body mass index (kg/m2) 26.4 (0.5) 25.9 (0.5) 25.3 (0.5) 26.6 (0.4) 27.1 (0.5) .06
Blood pressure (mmHg)
Systolic 152 (2.7) 157 (2.7) 161 (3.2) 153 (2.6) 160 (2.8) .29
Diastolic 82 (1.3) 84 (1.3) 84 (1.6) 83 (1.3) 88 (1.4) .03
Cholesterol (mmol/L) 5.5 (0.13) 5.9 (0.13) 6.2 (0.16) 5.4 (0.13) 5.7 (0.14) .73
HDL-cholesterol (mmol/L) 1.1 (0.04) 1.1 (0.04) 1.1 (0.05) 1.2 (0.04) 1.2 (0.04) .17
LDL-cholesterol (mmol/L) 3.7 (0.12) 4.0 (0.12) 4.3 (0.14) 3.7 (0.12) 3.8 (0.13) .80
Triglycerides (mmol/L) 1.4 (0.08) 1.5 (0.08) 1.6 (0.10) 1.3 (0.08) 1.5 (0.08) .55
Current smoking (%) 10.3 19.1 17.0 11.3 15.0 .53
Follow-up (years) 6.4 (0.31) 6.4 (0.31) 6.2 (0.37) 6.1 (0.30) 6.0 (0.33) .07
All-cause mortality, % (n) 42.6 (29) 50.0 (34) 53.2 (25) 50.7 (36) 53.3 (32) .75
Results are age-adjusted mean (standard error) except for noted.
a Geometric mean.
significantly higher when only adjustment for age comparedmen. Mean cholesterol, triglycerides, HDL-cholesterol, and
LDL-cholesterol levels were higher with increasing HbA1c
concentration in Dutch men. The mean systolic blood pres-
sure was apparently higher for the elderly Finnish men than
for Dutch men, but the mean diastolic blood pressure was
not. More than half of the Dutch men in the highest quintile
of the HbA1c concentration were smoking while this was








ation coefficient between FPG and HbA1c was 0.60, be-
ween 2-hr glucose and HbA1c 0.49 and between FPG and
-hr glucose 0.68. The chi-square test statistic for homogene-
ty was 0.11 for HbA1c, 0.50 for FPG, and 0.01 for 2-hr
lucose, with P-values (1df) 0.10 for all. There was no
tatistical evidence rejecting the hypothesis that the two
tudies are homogeneous with respect to the effects sizes.
The hazard ratios for all three glycemic variables were
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596 593with those with additional adjustment for other risk factors
in Dutch men, but not in Finnish men (Fig. 1). Multivariate
adjustment for other known risk factors studied did not
reduce the hazard ratios in the elderly Finnish men. The
multivariate adjusted hazard ratios for mortality did not sig-
nificantly differ between the two cohorts, although it tended
to be lower for fasting glucose in the elderly Finnish men
(see Fig. 1). Mortality increased linearly with increasing
2-hr glucose, HbA1c, and fasting glucose concentrations,
but the increase was significant only for the former two
when data for the two cohorts were combined (see Fig. 1).
Men at the upper 20% of the 2-hr glucose distribution
had a higher risk for death than men at the lower 80% of
the distribution (Table 3). This did not change after adjust-
ment for other risk factors studied and for HbA1c. Within
each category of HbA1c, there was an increasing trend
in hazard ratios with increasing 2-hr glucose levels, although
it was statistically significant only in the lowest HbA1c
category. Within each 2-hr glucose category, the hazard ratios
increased also with increasing HbA1c levels, but the in-
creasing trend was significant only in the lowest category
of 2-hr glucose (see Table 3).
Compared with men with normal glycemia (2-hr glucose
7.8 mmol/L and FPG 7.0 mmol/L and HbA1c 6.5%),
men who were impaired glucose tolerant or diabetic ac-
cording to the 2-hr plasma glucose 7.8 mmol/L but nondia-
betic according to FPG 7.0 mmol/L and HbA1c 6.5%,
had a significantly increased risk of death (Fig. 2). In con-
























Fig. 1. Hazard ratios (column) and their 95% confidence intervals (vertical bar) for a one standard deviation increase in HbA1c (%, inclined line), in fasting
(blank), and in 2-hr glucose (mmol/L, squared line) in men without prior history of diabetes, adjustment for age and cohorts if both studies combined (A),
and additional adjustment for body mass index, systolic blood pressure, HDL-cholesterol, triglycerides and smoking (B). One standard deviation in Dutch
(Finnish) men was 0.68% (0.66%) for HbA1c, 1.08 mmol/L (0.78 mmol/L) for fasting and 2.93 mmol/L (2.68 mmol/L) for 2-hr plasma glucose.
ere predictors of all-cause mortality in Dutch and Finnishlucose 11.1 mmol/L but diabetic according to FPG 7.0
mol/L and/or HbA1c 6.5%, the risk of death did not
iffer from men who were normal. Given the same FPG and
bA1c levels, the risk of death was 56% higher for men with
-hr glucose 11.1 mmol/L and 35% higher for men with
-hr glucose 7.8 mmol/L, compared with men whose 2-
r glucose was less than 11.1 mmol/L and less than 7.8
mol/L, respectively. Men who had prior history of diabetes
ad the highest risk for death. Multivariate adjustment did
ot substantially change the observed risk of death.
Addition of the 2-hr glucose to the model based on both
he fasting glucose and HbA1c significantly improved the
rediction (χ2  4.2, 1df., P  .05), whereas neither HbA1c
χ2  2.8, 1 df., P  .05) nor fasting glucose (χ2  1.2, 1
f., P  .10) improved the prediction once the 2-hr glucose
as in the model.
The interaction terms of center with glycemic variables
r center with other variables were not significantly associ-
ted with the mortality, except a positive association for
nteraction of center with body mass index. But when the
nalysis was further stratified with centers, body mass index
as not significantly associated with all-cause mortality in
ach of the two centers.
. Discussion
Our data show that HbA1c and 2-h glucose concentration
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596594Table 3
Hazard ratios of all-cause mortality by HbA1c and 2-h or fasting glucose categories
Percentiles of HbA1c (%)
40th 40th–80th 80th P-value for trend All
Adjustment for age and center
Percentiles of 2-h glucose (mmol/L)
40th 1 1.33 (0.87–2.03) 1.76 (1.06–2.92) 0.01 1
40th–80th 1.46 (0.97–2.20) 1.45 (0.96–2.17) 1.74 (1.09–2.78) 0.57 1.21 (0.94–1.56)
80th 1.47 (0.82–2.62) 1.81 (1.14–2.88) 2.09 (1.35–3.25) 0.26 1.48 (1.11–1.96)
P-value for trend 0.08 0.24 0.42
Percentiles of fasting glucose (mmol/L)
40th 1 1.08 (0.73–1.61) 1.14 (0.67–1.95) 0.53 1
40th–80th 0.90 (0.60–1.36) 1.12 (0.76–1.63) 1.74 (1.15–2.61) 0.004 1.11 (0.87–1.42)
80th 1.25 (0.70–2.21) 1.47 (0.95–2.28) 1.46 (0.95–2.26) 0.70 1.35 (1.01–1.79)
P-value for trend 0.71 0.22 0.53
All 1 1.19 (0.92–1.53) 1.50 (1.14–1.99)
Multivariate adjustmenta
Percentiles of 2-h glucose (mmol/L)
40th 1 1.27 (0.83-1.94) 1.63 (0.98-2.71) 0.02 1
40th–80th 1.52 (1.00-2.30) 1.41 (0.93-2.12) 1.55 (0.97-2.50) 0.96 1.23 (0.95–1.59)
80th 1.50 (0.83-2.68) 1.90 (1.18-3.05) 1.86 (1.18-2.94) 0.55 1.49 (1.10–2.01)
P-value for trend 0.03 0.23 0.56
Percentiles of fasting glucose (mmol/L)
40th 1 0.98 (0.65–1.47) 1.02 (0.60–1.75) 0.96 1
40th–80th 0.86 (0.57–1.30) 1.07 (0.73–1.56) 1.50 (0.99–2.27) 0.01 1.09 (0.85–1.40)
80th 1.21 (0.68–2.14) 1.45 (0.93–2.26) 1.23 (0.78–1.94) 0.86 1.30 (0.97–1.75)
All 1 1.14 (0.88–1.48) 1.33 (0.99–1.77)
P-value for trend 0.98 0.29 0.32
The lowest category of HbA1c and 2-h (fasting) glucose is used as reference group for HbA1c and 2-h (fasting) combined categories; the lowest category
of HbA1c or 2-h or fasting glucose alone is used for “All” category.
The cutoff values of lower, middle, and higher categories of HbA1c for Dutch men (Finnish men) were 5.2 (5.3), 5.3–5.7 (5.4–6.1) and 5.8 (6.2);
for 2-h glucose categories 4.9 (6.6), 5.0–7.0 (6.7–9.4) and 7.1 (9.5) and for fasting glucose categories 5.3 (5.4), 5.4–6.0 (5.5–6.2) and 6.1 (6.3).
a Adjusted for age, center, body mass index, systolic blood pressure, HDL-cholesterol, triglycerides, and smoking.men. The association was independent of other established
cardiovascular risk factors measured. The association of ele-
vated HbA1c with high-mortality risk, however, partly
depended statistically on the level of 2-hr glucose.
Population-based studies on the association of HbA1c
with risk of death are rare. One prospective study showed
that HbA1 (the sum of A1a, A1b, and A1c) is a better
predictor of cardiovascular mortality than FPG or 2-hr glu-
cose in women without diabetes, but not in men [9]. Subjects
with newly diagnosed diabetes (2-hr glucose 11.1 mmol/L
or FPG 7.8 mmol/L) were, however, not included in that
study, and therefore the effect of postload hyperglycemia
and the effect of fasting hyperglycemia on mortality were not
evaluated simultaneously. Based on a prospective population
study of 4,662 men aged 45–79 years, Khaw et al. [12]
reported that HbA1c was continuously related to subsequent
all-cause, cardiovascular, and ischemic heart disease mortal-
ity through the whole population distributions, with lowest
rates in those with HbA1c concentration below 5%. In their
study, fasting and 2-hr glucose were not taken into account
either. In people at risk for diabetes, postchallenge glucose
and glycemic excursions were found to be more strongly
associated with carotid intima-media thickness than fasting
glucose or HbA1c level [21]. Recently, the Framingham

























s a risk factor for incident CVD, independent of fasting
lucose and HbA1c levels, and the relation was stronger in
lderly population than in young populations [11]. That
-hr glucose was a better predictor for all-cause mortality
han FPG or HbA1c in men and women combined in the
oorn study has been reported previously, but the three-
lycemic variables were not adjusted simultaneously [10].
n addition, because of the limit of the statistical power,
urther detailed analysis based on any of the single study
annot be made properly.
Glycated hemoglobin is an indirect measure of integrated
lucose level over the previous 2–3 months [22]. The present
bservation, that part of the association of HbA1c with mor-
ality risk is explained by 2-hr glucose, may reflect the
ontribution of postprandial glucose levels to individual
bA1c levels. The fitting with the three highly correlated
lycemic measures in one model may, however, cause con-
ern. Yet, if collinearity were the only explanation for the
ack of independent effects of HbA1c or FPG when modeling
ogether with 2-hr glucose, the risk with 2-hr glucose would
lso have been diminished in multivariate model. The fact
hat the 2-hr postload hyperglycemia remains a consistent in-
ependent risk predictor for all-cause mortality, regardless
f model used, argues for a true independent effect.
Available evidence on the relationship between acute gly-
emic variations and diabetic complications was reviewed
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596 595Fig. 2. Hazard ratios (column) and their 95% confidence intervals (vertical bar) for combined glycemic categories and for previous diagnosed diabetes,
adjustment for age, cohorts, and additional adjustment for body mass index, systolic blood pressure, HDL-cholesterol, triglycerides, and smoking.recently by Ceriello [23]. The author concluded that acute
increases in blood glucose level after a meal appear to
be harmful, and can induce alterations of homeostasis in
healthy subjects, and even in diabetic subjects whose base-
line plasma glucose is in the hyperglycemic range [23].
The mechanisms through which acute hyperglycemia exert
its effects may be identified in labile nonenzymatic glycation,
promotion of thrombosis, and in production of free radicals.
Alternatively, the effect of 2-hr glucose may reflect other
metabolic disturbances, like dyslipidemia, insulin resistance,
hypertension, and abdominal obesity because glucose intol-
erance often appears together with these risk factors [24,25].
However, multivariate adjustment of the risk factors includ-
ing fasting insulin, a surrogate indicator for insulin resis-
tance, did not significantly change the results. However,
abdominal obesity as well other factors that were not mea-
sured were not adjusted for and the confounding effect of
the unmeasured factors could not be estimated, and need to
be further studied. More recently, Ceriello et al. [26] showed
an independent and cumulative deleterious effect of both
postprandial hypertriglyceridemia and postload hyperglyce-





















nd in healthy controls, and suggested that oxidative stress is
he common mediator through which they exert such an effect.
Although there is growing epidemiologic evidence show-
ng that postload hyperglycemia is an important risk factor
or future morbidity or mortality [1–7,27], the clinical trials,
o far, have not been designed to study the benefit of lower-
ng specifically the postload blood glucose levels. The land-
ark trial in this area, the UK Prospective Diabetes Study
UKPDS) [28], did not find convincing evidence supporting
he hypothesis that lowering fasting blood glucose concentra-
ion by intensive treatment with sulphonylurea or insulin
an reduce the risk of all-cause mortality. But in the UKPDS,
ostload glucose excursion, was not available, and over 10
ears, the difference in Hba1c concentration between inten-
ive and conventional groups was only 0.9% (7.0 vs. 7.9%).
There are different techniques for the measurement of
bA1c. Even techniques that use the same analytical method
ften report dissimilar values because of both the lack of
tandardisation in HbA1c measurement and the variability
n performance between instruments [29]. In this study, the
igh-performance liquid chromatograph method (HPLC)
as used for measurement of HbA1c in both centres, which
Q. Qiao et al. / Journal of Clinical Epidemiology 57 (2004) 590–596596reduced the variation that may be related to analytic methods.
However, we did not standardize the measurement of HbA1c.
The lack of standardisation would not affect the association
observed between HbA1c and mortality because a stratified
analysis based on each individual study was applied, and the
center was used as a covariate in the pooled analysis.
We conclude that elevated 2-hr glucose was a risk predictor
of all-cause mortality, independent of the levels of fasting glu-
cose and HbA1c in Dutch and Finnish men aged 50–89 years.
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